QPPV.COM KNOWLEDGE ASSESSMENT

Monoclonal Antibodies: Biology, Development and Pharmacovigilance

Test your understanding of the concepts covered by Monoclonal Antibodies: Biology, Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most appropriate use of a known mechanism of action during signal evaluation?

To establish causality whenever the event is biologically plausible To replace the need for clinical and epidemiological evidence To generate and refine a safety hypothesis that must be assessed against the totality of evidence To classify the event automatically as a class effect

Question 2 of 10 A patient develops toxicity after receiving the same nominal dose as before, but disease activity and target expression have changed. Which interpretation is most appropriate?

The dose is unchanged, so exposure must be unchanged The altered disease and target context could have changed target-mediated disposition and effective exposure The event cannot be drug-related because no dose increase occurred Only the administration route can influence exposure

Question 3 of 10 A patient experiences an adverse event after switching between two related biological products. What is the most appropriate assessment principle?

The switch caused the event because it was the most recent treatment change The event should be ignored because related products are scientifically similar The event requires reconstruction of treatment history and consideration of timing, alternatives and product-specific exposure Only the first product received should be recorded

Question 4 of 10 Which statement best describes the pharmacovigilance significance of humanised or fully human antibody sequences?

They eliminate the possibility of anti-drug antibodies They generally remove the need for immunogenicity assessment They may reduce some non-human sequence-related risks, but unwanted immune responses remain possible and context-dependent They guarantee equivalent immunogenicity across all products

Question 5 of 10 When evaluating an infusion-related reaction, which combination of information is especially relevant?

Only the product's antibody subclass Timing, infusion rate, premedication, prior exposure and recurrence on re-exposure Only the patient's age and sex Only whether the event was reported spontaneously

Question 6 of 10 Why should apparent immunogenicity rates not be compared across studies without examining assay methods?

Because immunogenicity can only be measured in spontaneous reports Because assay sensitivity, specificity and design can affect the apparent detection rate Because all studies use identical assays by definition Because treatment duration has no influence on detection

Question 7 of 10 Why should a positive anti-drug antibody result not automatically be classified as an adverse reaction?

Anti-drug antibodies are never clinically relevant The result is an analytical observation whose significance depends on persistence, titre, neutralising activity, timing and clinical consequences Laboratory findings are excluded from pharmacovigilance Only neutralising antibodies can be detected analytically

Question 8 of 10 Why may the relationship between dose and exposure for a monoclonal antibody be nonlinear?

Because all parenteral products have unpredictable absorption Because target-mediated binding can contribute to elimination and vary with dose or target abundance Because monoclonal antibodies are converted into small molecules after administration Because pharmacodynamic biomarkers always increase proportionally with dose

Question 9 of 10 Which workflow most closely reflects the article's recommended practical model for monoclonal-antibody safety assessment?

Class knowledge → automatic product conclusion → regulatory action Product identity and exposure reconstruction → clinical and biological assessment → evidence integration → benefit–risk evaluation Manufacturing review → exclusion of clinical data → risk minimisation Case count → presumed causality → class labelling

Question 10 of 10 Which statement best reflects the relationship between monoclonal-antibody pharmacovigilance and the EU pharmacovigilance framework?

Monoclonal antibodies are governed by an entirely separate pharmacovigilance system Their biological characteristics determine scientific areas of focus, but they remain within the general pharmacovigilance framework Scientific considerations automatically create new legal obligations General signal-management principles do not apply to biological medicines

QPPV.com

Monoclonal Antibodies: Biology, Development and Pharmacovigilance

Cookie Settings